Surmodics | SRDX - Sales Revenues


Surmodics reported $29.57M in Sales Revenues for its fiscal quarter ending in June of 2025.





Sales Change Date
Abbott USD 11.16B 300M Mar/2026
Align Technology USD 1.04B 10M Mar/2026
Anika Therapeutics USD 30.62M 2.8M Dec/2025
Arrowhead Research USD 264.03M 7.56M Dec/2025
Artivion USD 115.99M 2.6M Dec/2025
Baxter International USD 2.7B 270M Mar/2026
Boston Scientific USD 5.2B 90M Mar/2026
EDAP TMS EUR 13.88M 2.16M Sep/2025
Edwards Lifesciences USD 1.65B 80M Mar/2026
Haemonetics USD 338.97M 11.97M Dec/2025
Heron Therapeutics USD 40.59M 2.38M Dec/2025
J&J USD 24.1B 500M Mar/2026
Merit Medical Systems USD 381.9M 12M Mar/2026
Mesa Laboratories USD 62.84M 5.01M Dec/2024
Nektar Therapeutics USD 21.81M 2.32M Dec/2025
Option Care Health USD 1.35B 120M Mar/2026
Stryker USD 6B 1.2B Mar/2026
Surmodics USD 29.57M 355K Jun/2025
Trinity Biotech USD 14.31M 1.55M Sep/2025